Conclusions
In summary, although transferred patients are more likely to receive antiplatelet and anticoagulant therapies before catheterization laboratory arrival, these therapies are often delayed and dosed in excess among transfer patients compared with direct-arrival STEMI patients treated with primary PCI. This may, in part, contribute to the association of transfer status with greater bleeding risk. These results highlight an important target for quality improvement in the care of transferred STEMI patients.